In BC, the outcome of human epidermal growth factor receptor (HER)2-positive metastatic disease has fundamentally improved since the development of effective HER2 targeting agents, such as trastuzumab, pertuzumab, and trastuzumab–emtansine. This evidence concerns the gene ERBB2 and metastatic neoplasm.